Our proprietary particle-engineering technologies underpin a portfolio of respiratory product candidates for which we are seeking development partners.
Our NIOX® products accurately measure the concentration of fractional exhaled nitric oxide (FeNO) in asthma patients’ breath to help evaluate underlying airway inflammation.
